Trial number | Delivery system/route | mRNA encoding | Product name | Disease/virus | Phase | Start date (MM/YYYY) |
---|---|---|---|---|---|---|
COVID-19 | Â | Â | Â | Â | Â | Â |
 NCT04776317 | SAM-LNP, i.m | SARS-CoV-2 spike | NR | COVID-19 | I | 03/2021 |
 NCT04805125 | LNP, i.m | SARS-CoV-2 spike | mRNA-1273 | COVID-19 | III | 04/2021 |
 NCT04824638 | LNP, i.m | SARS-CoV-2 spike | BNT162b2 | COVID-19 | II | 03/2021 |
 NCT04900467 | LNP, i.m | SARS-CoV-2 spike | BNT162b2/mRNA-1273 | COVID-19 | NR | 05/2021 |
 NCT04961229 | LNP, i.m | SARS-CoV-2 spike | BNT162b2 | COVID-19 | IV | 10/2021 |
 NCT05124171 | LNP, i.m | SARS-CoV-2 spike | BNT162b2 | COVID-19 | III | 12/2021 |
 NCT05428592 | LNP, i.m | SARS-CoV-2 spike | LVRNA009 | COVID-19 | III | 04/2023 |
 NCT05549206 | LNP, i.m | SARS-CoV-2 spike (Omicron BA.5) | LVRNA012 | COVID-19 | NR | 04/2023 |
 NCT05599802 | LNP, i.m | SARS-CoV-2 spike variant | LVRNA010 | COVID-19 | I | 02/2023 |
 NCT05602961 | LNP, i.m | SARS-CoV-2 spike | GLB-COV2-043 | COVID-19 | I/II | 02/2023 |
 NCT05609045 | LNP, i.m | SARS-CoV-2 Omicron variant | RH109 | COVID-19 | I | 06/2023 |
 NCT05658523 | LNP, i.m | SARS-CoV-2 spike | Moderna/Novavax | COVID-19 | III | 02/2023 |
 NCT05672355 | MVA, i.m | SARS-CoV-2 spike | GEO-CM04S1 | COVID-19 | II | 09/2023 |
 NCT05682638 | LNP, i.m | SARS-CoV-2 spike | LVRNA009 | COVID-19 | III | 01/2023 |
 NCT05743335 | LNP, i.m | SARS-CoV-2 spike | JCXH-221 | COVID-19 | I/II | 03/2023 |
 NCT05745545 | LNP, i.m | SARS-CoV-2 spike (Omicron BA.5) | NR | COVID-19 | NR | 02/2023 |
 NCT05749926 | LNP, i.m | SARS-CoV-2 spike (Omicron BA.5) | BNT162b2/Sanofi | COVID-19 | III | 05/2023 |
 NCT05788185 | LNP, i.m | SARS-CoV-2 spike | RVM-V001/RVM-V002 | COVID-19 | I/II | 03/2023 |
 NCT05812014 | LNP, i.m | SARS-CoV-2 spike | LVRNA021 | COVID-19 | III | 03/2023 |
 NCT05815498 | LNP, i.m | SARS-CoV-2 spike | mRNA-1283.222 | COVID-19 | III | 03/2023 |
 NCT05827926 | LNP, i.m | SARS-CoV-2 spike + HA | mRNA-1083 | COVID-19/Influenza | I/II | 04/2023 |
 NCT05875701 | LNP, i.m | SARS-CoV-2 spike | Novavax | COVID-19 | III | 03/2023 |
 NCT05907044 | LNP, i.m | SARS-CoV-2 spike (Alpha, Beta + Omicron XBB.1.5/Alpha, Beta + Omicron BA.2, 4, 5) | RQ3027/RQ3025 | COVID-19 | NR | 05/2023 |
 NCT05911087 | LNP, i.m | SARS-CoV-2 spike | SWIM816 | COVID-19 | II/III | 06/2023 |
Cancer | Â | Â | Â | Â | Â | Â |
 mRNA-based vaccine |  |  |  |  |  |  |
  NCT03897881 | LNP, i.m | Neoantigen | mRNA-4157 | Stage III/IV melanoma | IIb | 07/2019 |
  NCT03908671 | LNP, s.c | Neoantigen | PCV | EC/NSCLC | I | 10/2019 |
  NCT04161755 | LNP, i.v | Neoantigen | PCV | PC | I | 12/2019 |
  NCT04382898 | LNP, i.v | 4 cancer antigens | BNT112 | mCRPC/LPC | II | 12/2019 |
  NCT04683939 | LNP, i.v | CLDN18.2 | BNT141 | GC/PC/OC/BTC | II | 01/2022 |
  NCT05761717 | LNP, s.c | Personalised cancer antigen | NR | Postoperative HC | NR | 04/2023 |
  NCT05738447 | LNP, i.m | HBsAg | HBV vaccine | HC | I | 02/2023 |
 mRNA-based cell therapy |  |  |  |  |  | |
  NCT01197625 | i.v | hTERT/Survivin | DC vaccine | PrCa | II | 09/2010 |
  NCT04503278 | RNA-LPX, i.v | CLDN6 | BNT211 | Advanced solid tumors | I/IIa | 09/2020 |
  NCT04981691 | i.v | MESO | Amaretto | Refractory malignant solid neoplasm | I | 10/2021 |
  NCT04984356 | i.v | CD7 | WU-CART-007 | T-ALL/LBL | I/II | 01/2022 |
 RiboMab (bispecific monoclonal antibody (mAb)-encoding mRNA) | ||||||
  NCT04683939 | LNP, i.m | CLDN18.2 | BNT141 | Multiple solid tumors | I/IIa | 01/2022 |
Infectious disease | Â | Â | Â | Â | Â | Â |
 NCT04917861 | LNP, i.m. | Zika | mRNA-1893 | Flavivirus | II | 06/2021 |
 NCT05085366 | LNP, i.m. | gB | mRNA-1647 | CMV | III | 10/2021 |
 NCT05127434 | LNP, i.m. | preF glycoprotein | mRNA-1345 | RSV-LRTD | II/III | 11/2021 |
 NCT05164094 | LNP, i.m. | EBV gB (gB/gH/gL/gp42/gB350) | mRNA-1189 | EBV | I | 12/2021 |
 NCT05217641 | LNP, i.m. | BG505 MD39.3/BG505 MD39.3 gp151/BG505 MD39.3 gp151 CD4KO | mRNA -1574 | HIV | I | 02/2022 |
 NCT05398796 | LNP, i.m. | pre-F/G | mRNA -1215 | Nipah virus | I | 07/2022 |
 NCT05414786 | LNP, i.p. | eOD-GT8 60mer | mRNA-1644 | AIDS | I | 05/2022 |
 NCT05415462 | LNP, i.m. | HA | mRNA-1010 | Seasonal influenza | III | 06/2022 |
 NCT05683457 | LNP, i.m. | gB | mRNA-1647 | CMV | II | 04/2023 |
 NCT05701800 | LNP, i.m. | zoster virus envelope glycoprotein E | mRNA-1468 | Herpes zoster | I/II | 01/2023 |
 NCT05743881 | LNP, i.m. | preF glycoprotein | mRNA-1345/mRNA-1365 | RSV-LRTD | I | 02/2023 |
 NCT05755620 | LNP, i.m. | HA | H1ssF-3928 | Influenza | I | 04/2023 |
 NCT05823974 | LNP, i.m. | NR | GSK4382276A | Influenza | I/II | 04/2023 |
 NCT05827068 | LNP, i.m. | HA | mRNA-1011.1/mRNA-1011.2/mRNA-1012.1 | Seasonal influenza | I/II | 03/2023 |
 NCT05827978 | LNP, i.m. | HA | mRNA-1010 | Seasonal influenza | III | 04/2023 |
 NCT05829356 | LNP, i.m. | Full-length HA sequence of A/Tasmania/503/2020 (H3N2) | NR | Influenza | I | 04/2023 |
 NCT05831111 | LNP, i.m. | EBV gB | mRNA-1195 | EBV | I | 04/2023 |
 NCT05868382 | LNP, i.m. | HA | mRNA-1010 candidate variations | Influenza | II | 05/2023 |
 NCT05905731 | i.v. | HBV-TCR | NR | CHB | I | 06/2023 |
Protein replacement | Â | Â | Â | Â | Â | Â |
 NCT04442347 | LNP, i.v. | OTC | ARCT-810 | OTCD | Ib |  |
Gene editing | Â | Â | Â | Â | Â | Â |
 In vivo |  |  |  |  |  |  |
  NCT04601051 | LNP, i.v. | TTR-targeted CRISPR-Cas9 | NTLA-2001 | ATTRv-PN/ATTR-CM | I | 11/2020 |
 Ex vivo |  |  |  |  |  |  |
  NCT03655678 | i.v. | BCL11A-targeted gRNA | CTX001 | TDT | III | 09/2018 |
  NCT04426669 | i.v. | CISH-targeted CRISPR-Cas9 | NR | GI cancer | I/II | 05/2020 |
  NCT05456880 | i.v. | HBG1/2 promoter-targeted CRISPR-Cas9 | BEAM-101 | SCD | I/II | 08/2022 |